| 赵海燕,苏乌云,呼 群,刘彩霞,赵瑞东,云霏雨,云 升.DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及对免疫功能的影响[J].,2017,17(13):2560-2564 |
| DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及对免疫功能的影响 |
| Effect of DC-CIK Combined with Chemotherapy on Advanced Non-small Cell Lung Cancer and Its Influence on Immune Function |
| 投稿时间：2017-01-22 修订日期：2017-02-19 |
| DOI：10.13241/j.cnki.pmb.2017.13.042 |
| 中文关键词: 非小细胞肺癌 DC-CIK免疫疗法 化疗 |
| 英文关键词: Non-small cell lung cancer DC-CIK immunotherapy Chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 518 |
| 全文下载次数: 279 |
| 中文摘要: |
| 摘要 目的：研究树突细胞-细胞因子诱导杀伤细胞（DC-CIK）免疫疗法联合化疗治疗晚期非小细胞肺癌（NSCLC）的疗效及对免疫功能的影响。方法：选取2014年1月至2015年12月就诊于我院的60例Ⅲb～Ⅳ晚期NSCLC患者，采用随机数字表法分为联合组和化疗组各30例。联合组采用DC-CIK免疫疗法联合化疗（顺铂+吉西他滨），1个月为一个周期。化疗组仅进行单纯化疗，1个月为一个周期。比较两组患者近期疗效、无进展生存期（PFS）、总生存期（OS）、免疫功能、生活质量以及不良反应。结果：联合组DCR显著高于化疗组（P＜0.05），联合组的中位PFS高于化疗组（P＜0.05）。联合组治疗后外周血中的CD3+、CD3+CD4+和NK细胞较治疗前显著上升（P＜0.05），CD3+CD8+细胞较治疗前显著下降（P＜0.05），且治疗后联合组的CD3+、CD3+CD4+和NK细胞较化疗组显著上升（P＜0.05），CD3+CD8+细胞较化疗组显著降低（P＜0.05）。联合组疲乏、疼痛、食欲不振、睡眠障碍发生率低于化疗组（P＜0.05）。联合组白细胞减少率、血小板减少率显著低于化疗组（P＜0.05）。结论：DC-CIK联合化疗治疗NSCLC患者的疗效显著，可提高DCR，延长患者的PFS，提高患者的免疫功能和生活质量，减少不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy combined with chemotherapy on advanced non-small cell lung cancer (NSCLC) and its influence on immune function. Methods: Sixty patients with stage Ⅲb~Ⅳ NSCLC treated in our hospital from January 2014 to December 2015,they were divided into combined group and chemotherapy group according to the random number table method, with 30 patients in each group. Combined group was treated with DC-CIK immunotherapy combined with chemotherapy (cisplatin+gemcitabine), 1 month for a cycle, while the chemotherapy group was only treated with chemotherapy, 1 month for a cycle. The short-term efficacy, progression-free survival (PFS), overall survival (OS), im- mune function, life quality, and adverse reactions were compared between the two groups. Results: DCR in combined group was signifi- cantly higher than chemotherapy group (P<0.05). The median PFS of combined group was higher than chemotherapy group (P<0.05). CD3+, CD3+CD4+ and natural killer (NK) cells in the peripheral blood of the combined group increased significantly after treatment (P<0.05), and CD3+CD8+ cells significantly decreased after treatment (P<0.05). CD3+, CD3+CD4+ and NK cells in combined group were signif- icantly higher than chemotherapy group after treatment (P<0.05), CD3+CD8+ cells were significantly lower than chemotherapy group after treatment (P<0.05). The incidence of fatigue, pain, loss of appetite and sleep disorder in combined group were significantly lower than chemotherapy group (P<0.05). The rate of leukopenia and thrombocytopenia in combined group were significantly lower than chemotherapy group (P<0.05). Conclusion: DC-CIK combined with chemotherapy has obvious effect in the treatment of advanced NSCLC, which could improve the DCR, prolong PFS, improve immune function and improve life quality, reduce adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
